Galectin Therapeutics Inc.
Galectin Therapeutics Inc. (Nasdaq: GALT) is a clinical-stage biopharmaceutical company developing carbohydrate-based drug candidates that target galectin proteins, particularly galectin-3, for fibrotic diseases and cancer. Its lead candidate, belapectin, is being developed primarily to prevent esophageal varices in… From the company’s description.
In fiscal 2025, Galectin Therapeutics Inc. reported a net loss of $30.84M. Operations used $23.88M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Galectin Therapeutics Inc. does
In the company’s own words
Galectin Therapeutics Inc. (Nasdaq: GALT) is a clinical-stage biopharmaceutical company developing carbohydrate-based drug candidates that target galectin proteins, particularly galectin-3, for fibrotic diseases and cancer. Its lead candidate, belapectin, is being developed primarily to prevent esophageal varices in patients with cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH); the company is also pursuing belapectin with a checkpoint inhibitor for recurrent or metastatic head and neck cancer. Its programs include clinical development of belapectin and an early discovery effort through majority-owned Galectin Sciences LLC to develop small-molecule galectin-3 inhibitors that may allow oral administration. The company outsources research, clinical trials, manufacturing and, if products reach market, may use third parties for sales and marketing; it has no approved products. Belapectin is made from plant-derived starting materials and formulated as a pharmaceutical product. Galectin Therapeutics reported research and development expenses of $14.3 million for fiscal 2025. Its website is www.galectintherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NORCROSS, GA
- Fiscal year end
- December
- CIK
- 1133416
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Galectin Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Galectin Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Galectin Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Galectin Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Galectin Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”